Oral Icotrokinra for Plaque Psoriasis in Adults and Adolescents

Selective blockade of the interleukin-23 receptor with the targeted oral peptide icotrokinra resulted in a significantly higher incidence of skin clearance at week 16 than placebo among adults and adolescents with moderate-to-severe plaque psoriasis. Longer-term data will provide a more complete understanding of the benefit-risk profile of icotrokinra. (Funded by Johnson & Johnson; ICONIC-LEAD ClinicalTrials.gov number, NCT06095115.)See also in <i>NEJM Evidence</i>: Targeted Oral Peptide Icotrokinra for Psoriasis Involving High‑Impact Sites.